2707 |
Outcomes of PCI vs. CABG: Current and Future |
Young-Hak Kim |
May. 08. 14 |
2706 |
Radial Approach for Complex LM Lesions |
Kenji Wagatsuma |
May. 08. 14 |
2705 |
When PCI Is the Preferred Revascularization Strategy for LM Disease |
Michael S. Lee |
May. 08. 14 |
2704 |
Ticagrelor Beyond Antiplatelet Effect & Benefit in \"Real-World\" Practice |
Dimitrios Alexopoulos |
May. 08. 14 |
2703 |
Statin for Better Outcome in Patients with ACS |
Kyung Woo Park |
May. 08. 14 |
2702 |
Anticoagulant Therapy in ACS: Should Bivalirudin Be the Anticoagulant of Choice for STEMI Intervention? - Against: No, Heparin with Provisional GPI Remains in the Standard of Care! |
Neal S. Kleiman |
May. 08. 14 |
2701 |
Anticoagulant Therapy in ACS: Should Bivalirudin Be the Anticoagulant of Choice for STEMI Intervention? - For: Yes, It Is So Simple and Really Effective! |
Mun Kyung Hong |
May. 08. 14 |
2700 |
Pretreatment with P2Y12 Inhibitors: Is It Necessary Prior to PCI in NSTE-ACS? - Against: No, Little Evidences, No Benefits! |
Philippe Garot |
May. 08. 14 |
2699 |
Pretreatment with P2Y12 Inhibitors: Is It Necessary Prior to PCI in NSTE-ACS? - For: Yes, Nothing to Lose, Everything to Gain! |
Sorin Brener |
May. 08. 14 |
2698 |
Symplicity HTN 3: Where Are We Going to? |
David E. Kandzari |
May. 08. 14 |